This article was originally published in The Tan Sheet
Sale of unfinished dextromethorphan would be restricted to entities registered with FDA under the "Dextromethorphan Distribution Act of 2006" (HR 5280) introduced May 3 by Reps. Fred Upton (R-Mich.) and Rick Larsen (D-Wash.). The cough suppressant bulk ingredient has been abused by "individuals, including teenagers," the bill notes. The HHS Secretary will be required to issue a final rule restricting distribution of unfinished dex within 180 days of enactment if the bill passes. The Consumer Healthcare Products Association applauded the measure. FDA drew attention to concerns about bulk dex abuse through a May 2005 "Talk Paper" (1"The Tan Sheet" May 30, 2005, p. 3)...
You may also be interested in...
The Consumer Healthcare Products Association is actively working to encourage introduction of companion legislation in the Senate for a bill that would restrict the sale and distribution of bulk forms of dextromethorphan
An FDA "Talk Paper" is raising the profile of dextromethorphan (DXM) abuse issues from a peripheral concern to a visible public health problem
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.